Which medication class is not known to reduce mortality in heart failure with reduced EF?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards

From $25.99Unlock all

Study for the NBME Form 13 Test with our comprehensive quiz collection, featuring flashcards and multiple-choice questions to ensure your readiness. Enhance your knowledge with detailed explanations for each question.

Multiple Choice

Which medication class is not known to reduce mortality in heart failure with reduced EF?

In heart failure with reduced ejection fraction, improving survival comes from therapies that blunt detrimental neurohormonal activation and remodeling. Beta-blockers, RAAS inhibitors (ACE inhibitors/ARBs), and aldosterone antagonists have solid trial evidence showing mortality reduction. Calcium channel blockers, on the other hand, do not confer a survival benefit in this setting. They can worsen contractility in a failing heart, and trials with agents like amlodipine and felodipine showed no mortality improvement, with some non-dihydropyridine CCBs causing negative inotropy. So the medication class not known to reduce mortality in HFrEF is calcium channel blockers.

Which medication class is not known to reduce mortality in heart failure with reduced EF?

Study for the NBME Form 13 Test with our comprehensive quiz collection, featuring flashcards and multiple-choice questions to ensure your readiness. Enhance your knowledge with detailed explanations for each question.

Which medication class is not known to reduce mortality in heart failure with reduced EF?

Get the latest from Passetra